Case Study: Stem Cell Therapy for Multiple System Atrophy (MSA)

A Four-Year Journey With Autonomic Dysfunction, Balance Problems, Tremor and Progressive Disability. What is it Stem Cell Therapy for Multiple System Atrophy (MSA)?

Patient: Zhang Min
Age: 57 years
Diagnosis: Multiple System Atrophy (MSA)
Time since diagnosis: 4 years
Follow-up described in this case: 12 months

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder affecting several systems of the nervous system. It can combine autonomic dysfunction, parkinsonism, impaired balance, gait problems, tremor, rigidity and cerebellar symptoms. Because early MSA can resemble Parkinson's disease, establishing the correct diagnosis may be challenging, particularly when autonomic and motor symptoms develop together.

This case study describes the clinical history of Zhang Min, a 57-year-old patient diagnosed with MSA four years before treatment. The patient's symptoms initially suggested another movement disorder, and he was consequently treated as having Parkinsonism. As the disease progressed and the response to treatment became unsatisfactory, the diagnosis was subsequently confirmed as Multiple System Atrophy.

The treatment described in this case used a multimodal cell-based regenerative approach involving mesenchymal stromal cells, neural progenitor-related cells, neurotrophic and mRNA-based components, endothelial cells, extracellular vesicles, myoblasts and mitochondrial support.

Important clinical note: This is an individual case study based on the treatment history supplied by the clinic. It does not establish that the treatment reverses, cures or permanently stops MSA. Current evidence for disease-modifying cell therapy in MSA remains investigational. A 2026 systematic review of seven MSC studies involving 123 participants found potentially slower disease progression in studies and the need for larger controlled trials.

Zhang Min's MSA History

The patient's first symptoms were predominantly related to autonomic regulation and movement control.

The illness initially manifested with:

• autonomic disturbances;
• impaired balance;
• progressive gait difficulties;
• increasing motor instability;
• development of tremor.

Because some of these features overlap with Parkinson's disease and other parkinsonian syndromes, the patient was initially diagnosed and treated for Parkinsonism.

Over time, however, his clinical condition continued to deteriorate. The expected therapeutic response was not achieved, neurological symptoms progressed, and the initial treatment was discontinued after the diagnosis was reassessed and Multiple System Atrophy was confirmed.

This diagnostic evolution is clinically relevant because MSA can present with a combination of autonomic and motor features that distinguishes it from typical Parkinson's disease. Modern Movement Disorder Society criteria incorporate autonomic dysfunction, parkinsonism, cerebellar dysfunction and other neurological findings into the diagnostic framework. MSA how to stop progression of disease

Treatment Approach in Stem Cell Therapy for Multiple System Atrophy (MSA)

According to the treatment record, Zhang Min received a multimodal cellular and regenerative medicine program.

MSCs — MUSE Cells

Mesenchymal stromal cells were included as the principal regenerative cell population.

MSCs are being investigated in neurodegenerative disorders because of their immunomodulatory, trophic and paracrine effects. Rather than functioning solely through direct replacement of damaged cells, MSCs may release signaling molecules that interact with surrounding cells and influence inflammatory and tissue-supportive pathways.

The 2026 systematic review of MSC therapy in MSA similarly concluded that the approach shows potential but requires larger, standardized studies before definitive conclusions can be made.

Neural Progenitor Cells

The protocol included neural progenitor-related cells described as iPSC-derived/MSC-associated neural progenitors, with neural-lineage components including neuroblasts and astrocytic-related cells.

The intended biological rationale was to support neuronal signaling and the cellular environment of the nervous system.

Neurotrophins and mRNA-Based Signaling Components

The treatment program also incorporated neurotrophic and mRNA-based components intended to support cellular communication and neuronal function.

Neurotrophic signaling is an important area of neuroscience research because growth factors can influence neuronal survival, synaptic function and cellular responses to injury.

Microvascular Endothelial Cells

Microvascular endothelial cells were included with the aim of supporting the vascular environment and angiogenic signaling.

The rationale is based on the relationship between vascular function and tissue homeostasis. Adequate microvascular function is necessary for oxygen and nutrient delivery and for maintaining a supportive extracellular environment.

Neural Exosomes / Extracellular Vesicles

The protocol included neural exosomes, described as signaling vesicles intended to support cell-to-cell communication.

Extracellular vesicles can carry proteins, lipids and nucleic-acid-associated signals and are an active area of regenerative medicine research.

Their potential role in neurological diseases includes modulation of inflammatory signaling and intercellular communication.

Myoblasts

Myoblasts were included with the objective of supporting muscle structure and physical function.

Because progressive neurological disease can lead to reduced mobility, weakness and secondary muscle deconditioning, preservation of muscle function can be an important component of comprehensive rehabilitation.

In this case, the cellular approach was combined with the broader objective of maintaining functional capacity.

Mitochondrial Complex

A mitochondrial-support component was used as part of the treatment program with the intention of supporting cellular energy metabolism and ATP production.

Mitochondrial biology is increasingly relevant to neurodegeneration because neurons have high energy demands and depend heavily on efficient cellular metabolism. Mitochondrial Therapy for Autoimmune Diseases: How Functional Mitochondria Support Immune Recovery, Tissue Regeneration, and Long-Term Health

Clinical Course After Stem Cell Therapy for Multiple System Atrophy (MSA)

According to the treatment follow-up, the patient's course showed a gradual change rather than an immediate transformation.

First 3 Months

During the first three months, individual symptoms reportedly became less pronounced.

The changes included a reduction in selected manifestations of the disease and improved overall functional status.

Eight Months

At approximately eight months, the patient was described as having reached clinical stabilization.

No new major complications were reported during this period.

The clinic documentation characterized this phase as a period of remission or stabilization. Because MSA is generally regarded as a progressive neurodegenerative disorder, the term clinical stabilization is more appropriate scientifically unless remission has been defined using a validated disease-specific measure.

Twelve Months

At the 12-month follow-up, the reported clinical result remained stable.

No significant deterioration was reported, and the improvements observed during the earlier follow-up period were described as maintained.

Before and After Stem Cell Therapy for Multiple System Atrophy (MSA)

The following table summarizes the reported clinical course rather than validated numerical scores. Advanced Regenerative Medicine Technologies and Cellular Laboratory Solutions at Mediland Stem Cell Therapy Center

Clinical Parameter	Before Treatment	3 Months	8 Months	12 Months
Autonomic symptoms	Present	Reduced in selected manifestations	Stabilized	Stable
Balance	Impaired	Improvement reported	Stabilized	Maintained
Gait	Progressive difficulty	Improvement reported	Stable	Maintained
Tremor / motor symptoms	Present	Individual symptoms reduced	Stabilized	No reported worsening
Functional disability	Progressive	Reduced according to clinical observation	Stabilized	Maintained
New complications	Disease progression before therapy	No major new complications reported	No new complications reported	No new complications reported
Overall clinical status	Progressive neurological decline	Early improvement	Clinical stabilization	Result maintained

Reported Reduction in Functional Disability

One of the most important observations in the case is the reported change in functional disability.

Before treatment, the patient's symptoms were progressively interfering with movement, balance and everyday functioning.

Following treatment, the clinical record describes a reduction in the severity of selected symptoms and subsequent stabilization.

What May Happen at the Cellular and Biochemical Level?

It is important to separate the biological rationale from demonstrated biochemical changes.

Neuroprotection

MSC-based therapy is being investigated in MSA primarily for potential neuroprotective and trophic effects, rather than simple replacement of lost neurons. The 2026 systematic review identified anti-inflammatory and trophic mechanisms as central hypotheses behind MSC therapy.

Immunomodulation

MSCs can interact with immune cells and influence inflammatory signaling. This makes them particularly interesting for neurodegenerative conditions in which inflammation and cellular stress may contribute to disease progression.

Cellular Energy Metabolism

Neural cells require continuous ATP production to maintain membrane potentials, synaptic signaling and axonal transport.

Mitochondrial support is therefore being investigated as a potential strategy for maintaining neuronal energy metabolism, although a clinical benefit in MSA has not been definitively demonstrated.

Neurotrophic Signaling

Neurotrophic factors may influence neuronal survival, differentiation and synaptic function. The addition of neurotrophic signaling components in this treatment approach was intended to support the neural cellular environment.

Extracellular Vesicle Signaling

Exosomes and other extracellular vesicles are involved in intercellular communication and may influence recipient-cell behavior through transported molecular signals.

These pathways provide a scientific rationale for investigation, but they do not yet establish that exosomes can regenerate the MSA-affected brain in humans.

Why Stabilization May Be Clinically Meaningful in MSA

MSA is generally considered a rapidly progressive neurodegenerative condition, with autonomic, parkinsonian and/or cerebellar manifestations. Recent prognostic research emphasizes the progressive nature of the disease and identifies several clinical factors associated with more unfavorable outcomes.

For this reason, a period of sustained clinical stability may be an important observation in an individual case.

In Zhang Min's case, the reported trajectory was:

Progressive symptoms → 3-month symptom reduction → 8-month stabilization → 12-month maintenance of the reported result.

A Multimodal Regenerative Medicine Strategy

The treatment was designed as a multimodal regenerative protocol, combining different cellular and cell-derived components rather than relying on a single intervention.

The intended areas of support included:

Immune regulation: MSC-mediated immunomodulation.

Neural support: neural progenitor-related cells and neurotrophic signaling.

Microvascular support: endothelial cells and angiogenic signaling.

Cellular communication: exosomes and extracellular vesicles.

Musculoskeletal support: myoblasts.

Energy metabolism: mitochondrial support.

Such a multimodal strategy is biologically interesting, but it also creates an important limitation for interpreting the case: when multiple interventions are administered together, it is impossible to determine which component contributed to an observed change.

What Does Current Research Say About Stem Cells for MSA?

The evidence base for stem cell therapy for Multiple System Atrophy is still developing.

A randomized study involving 33 patients with MSA-C found that the NSC group had a smaller increase in total and Part II UMSARS scores than the placebo group over 360 days. The study suggested that NSC therapy might delay progression, although an intra-arterial administration route was associated with small ischemic MRI lesions.

A 2026 systematic review synthesized seven clinical studies involving 123 patients. It found that adverse events were generally mild and transient and that several studies suggested slower progression after NSC therapy. Nevertheless, the review emphasized differences in cell dose, administration route, disease stage and study design and concluded that larger definitive trials are required.

Thus, the current research supports continued investigation of NSC therapy for MSA, but not a claim that stem cells are a proven cure or established disease-modifying treatment.

Conclusion: Zhang Min's 12-Month MSA Case

Zhang Min, a 57-year-old patient with a four-year history of Multiple System Atrophy, experienced progressive autonomic dysfunction, balance and gait impairment and tremor before receiving a multimodal cell-based treatment program.

According to the reported follow-up, individual symptoms decreased during the first three months. By approximately eight months, the patient's condition was described as clinically stabilized, without the appearance of new major complications. At 12 months, the reported clinical improvements remained stable without significant deterioration.

The case is notable for the reported reduction in functional disability and subsequent fixation of the result over one year.